Antiphospholipid syndrome primary prevention: Difference between revisions

	Antiphospholipid syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Antiphospholipid syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Antiphospholipid syndrome primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Antiphospholipid syndrome primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Antiphospholipid syndrome primary prevention
CDC on Antiphospholipid syndrome primary prevention
Antiphospholipid syndrome primary prevention in the news
Blogs on Antiphospholipid syndrome primary prevention
Directions to Hospitals Treating Antiphospholipid syndrome
Risk calculators and risk factors for Antiphospholipid syndrome primary prevention

Revision as of 20:17, 4 April 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

The primary prevention of antiphospholipid syndrome is as follows:

Anticoagulation in patients with risk factors for arterial and venous thrombosis.
Minimizing the contribution of reversible risk factors for recurrent thrombosis.

@@ Line 5: / Line 5: @@
 ==Primary Prevention==
-In addition to anticoagulation, attention should be paid to minimizing the contribution of reversible risk factors for recurrent thrombosis. During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis
+The primary prevention of antiphospholipid syndrome is as follows:
-[[Randomized controlled trial]]s have addressed the secondary prevention of thromboses. These trials include APLASA<ref name="pmid17599766">{{cite journal| author=Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L et al.| title=Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. | journal=Arthritis Rheum | year= 2007 | volume= 56 | issue= 7 | pages= 2382-91 | pmid=17599766 | doi=10.1002/art.22663 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17599766  }} </ref>,
+* Anticoagulation in patients with risk factors for arterial and venous thrombosis.
+* Minimizing the contribution of reversible risk factors for recurrent thrombosis.
 ==References==
 {{reflist|2}}
 [[Category:Disease]]